Around a quarter of patients could benefit from GLP-1 drugs, but few can afford monthly prices of $1,000-$1,400, creating significant disparities in access.
West Virginia, plagued by high obesity rates and poverty, exemplifies the divide in access to weight-loss medications, with insurance programs often not covering the costs.
Collection
[
|
...
]